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Molybdenum cofactor deficiency (MOCD) is a rare metabolic disorder with 
neurological symptoms of neonatal onset, developmental delay, seizures 
and motor abnormalities, first described in 1978 (1). If undiagnosed, this 
disorder can result in rapid progressive encephalopathy and death. Early 
diagnosis is important in this lethal disorder as treatment with cyclic 
pyranopterin monophosphate (cPMP) could arrest the progression of 
MOCD type A (2). 
We describe an infant with MOCD having early onset refractory seizures 
and imaging findings mimicked hypoxic-ischemic encephalopathy. 
Restricted diffusion was noted along the corticospinal tract in our patient. 
It is a novel imaging finding in patients with MOCD and a novel mutation 
Abstract 
Molybdenum cofactor deficiency is a rare metabolic disorder manifesting with 
early onset seizures, developmental delay, microcephaly, and spasticity.In this 
report, we describe a three-month-old infant with poorly controlled seizures of 
neonatal onset, developmental delay, microcephaly, spastic quadriparesis and 
cortical visual impairment. Magnetic resonance imaging of brain had shown 
cystic encephalomalacia involving bilateral parieto-occipital lobe and elevated 
lactate in magnetic resonance spectroscopy. Restricted diffusion noted along 
the corticospinal tract in our case is a novel imaging finding in patients with 
molybdenum cofactor deficiency. Low serum uric acid and elevated urine sulfite 
excretion were observed. A novel homozygous mutation was detected in exon 4 
of molybdenum cofactor synthesis 2 (MOCS2) gene. Early infantile or neonatal 
onset seizures, developmental delay, microcephaly and cystic encephalomalacia 
in neuroimaging mimicking hypoxic-ischaemic encephalopathy should raise 
the suspect for molybdenum cofactor deficiency. Screening of all neonates for 
urinary sulfite metabolites would help in early diagnosis and management. Early 
diagnosis and treatment with cyclic pyranopterin monophosphate could arrest the 
progression of molybdenum cofactor deficiency type A. More research is needed 
to explore further treatment options in this otherwise lethal disorder.
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was also detected in the exon 4 of molybdenum 
cofactor synthesis 2 (MOCS2) gene.
Case report
A three-month-old boy born first in birth order to a 
non-consanguineously married Indian couple was 
referred for the evaluation of global developmental 
delay and refractory seizures. Informed consent 
was taken from the mother. Mother had no 
antenatal risk factors. The baby was delivered full 
term by normal vaginal delivery with a birth weight 
of 3200 g. Neonatal transition was uneventful. 
Jaundice was noticed on third day of life and the 
maximum bilirubin recorded was 16.3 mg/dL. 
There was no ABO or Rh incompatibility and he 
was discharged home on exclusive breastfeeds. He 
was readmitted on eighth day of life with history 
of poor feeding and lethargy. Baby was initiated 
on intravenous fluids and antibiotics, after sending 
samples for sepsis screen. Sepsis workup was 
negative and he was discharged home, as there was 
a clinical improvement. At the end of second week 
of life, he presented to the Paediatric Emergency 
room with frequent episodes of multifocal clonic 
seizures. Blood sugar on arrival was 77 mg/dL 
and the seizures were managed with loading dose 
of phenobarbitone and phenytoin. There were no 
skin rashes, abnormal urine odor, fast breathing or 
recurrent hiccups. From second month of age, child 
had developed multiple episodes of myoclonus per 
day and seizures were poorly controlled despite 
treatment with three antiepileptic medications in 
adequate doses.
There were no neurocutaneous markers or 
dysmorphism. Occipto-frontal circumference 
was 36.5 cm. Ocular examination did not reveal 
any ectopia lentis. He was awake and irritable 
with inconsolable cry. He was also observed to 
have poor quality and quantity of spontaneous 
limb movements. He did not fix or track the light 
and fundus examination was normal. Pupillary 
reflexes were normal.Profound axial hypotonia, 
appendicular hypertonia and brisk deep tendon 
reflexes were observed. There were no involuntary 
movements. Anterior fontanelle was normal.
Complete blood count, blood urea, creatinine, 
electrolytes and liver function test were normal. 
Serum uric acid was less than 0.5 mg/dL. Blood 
lactate, ammonia, and serum amino acids were 
normal. Urinary organic acids were not detected. 
Cerebrospinal fluid analysis was normal. 
Electroencephalography done in the first month 
of life was normal. Freshly voided urine analysis 
by calorimetric method had revealed an increased 
sulfite excretion(patient value: 1425 µmol/L; 
normal: 0-96.7 µmol/L). 
Brain magnetic resonance imaging (MRI) 
(Figure 1A-C) revealed extensive cystic 
encephalomalacia involving bilateral parieto-
occipital lobe and signal changes involving caudate, 
putamen and deep white matter. Basal ganglia 
showed focal T2 hypointensity and corresponding T1 
hyperintensity (Figure 1D) predominantly involving 
head of the caudate and putamen bilaterally. This 
is most suggestive of early calcification although 
confirmatory CT brain was not done. Diffuse callosal 
thinning was also noted (Figure 2A). Restriction of 
diffusion was seen along the corticospinal tract in the 
diffusion weighted and apparent diffusion coefficient 
images (Figure 2B-C). Magnetic resonance 
spectroscopy (MRS) had shown an elevated lactate 
peak (Figure 1E-F). 
Diagnosis of MOCD was suspected based on the 
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Fig 1: MRI brain T2 axial (A) and FLAIR (B) images show bilateral parieto-occipital cystic encephalomalacia (red arrows) and 
deep white matter hyperintensities (black arrows). Volume loss and signal changes of caudate (blue arrow- single) and putamen 
(blue arrows- double) are seen in T2 axial (C) image. Corresponding T1 coronal image (D) shows hyperintense signal (blue 
arrows- single and double) which could represent early calcification. Also note the sparing of thalamus. MRS from parenchyma 
shows peak at TE 35 (E) with inversion at TE 144 (F) suggestive of lactate.
Fig 2: MRI brain T1 sagittal image (A) shows diffuse thinning of corpus callosum (white arrow); brainstem appear normal and 
cerebellum also appear normal (double arrows). DWI (B) and ADC (C) images show restricted diffusion along corticospinal tracts 
at the corona radiata (white arrows).
110
clinical, radiological findings and biochemical 
markers. MOCS1 and MOCS2 genes were 
sequenced by Sanger sequencing (primer 
sequences and conditions are available on request). 
A homozygous mutation was detected in exon 4 
of MOCS2 gene: NM_004531.4: c.218T>C which 
leads to substitution of Leucine at position 73 to 
Proline.Leucine at position 73 is a highly conserved 
residue across different species. This is a novel 
mutation which is not listed in dbsnp, ExAc and 
HGMD databases and predicted to be pathogenic 
by MutationTaster, FATHMM-MKL, LRT, SIFT, 
PROVEAN, and POLYPHEN prediction (DANN 
score 0.9984).
Child had partial head control but there was 
no   social smile, visual fixation to toys or startle 
response to loud sounds during a follow-up 
neurodevelopmental assessment at five months 
of age. He had poorly controlled seizures, 
microcephaly, spastic quadriparesis and cortical 
visual impairment. Child was managed with 
anticonvulsants and infant stimulation therapy. 
Despite all supportive measures and optimization 
of antiepileptic medications, child succumbed at 
nine months of age.
Discussion
Rare presentation of late-onset movement 
disorder has also been reported (3). MOCD 
results in the loss of function of sulfite oxidase, 
aldehyde oxidase, xanthine dehydrogenase and 
mitochondrial amidoxime reducing component 
(4). MOCD leads to an increased urinary excretion 
of sulfite, thiosulfate, S- sulfocysteine, taurine, and 
hypotaurines. MOCD leads to a decrease in the 
conversion of xanthine to uric acid resulting in low 
serum uric acid level. Sulfite accumulation is toxic 
to the proteins and sulfur containing aminoacids, 
thereby resulting in deranged cellular metabolism 
(4). Elevated sulfite has a neurotoxic effect and 
results in neuronal death (4). 
Early onset refractory seizures, microcephaly, 
progressive encephalopathy with or without 
dislocation of lens should cast a clue for the 
diagnosis of MOCD or isolated sulfite oxidase 
deficiency. Biochemical tests for the diagnosis 
of MOCD are low blood uric acid and elevated 
excretion of sulfite, thiosulfate, S-sulfocysteine, 
hypoxanthine, and xanthine in urine. Our patient 
had classical clinical phenotype, low blood uric 
acid level and elevated urinary excretion of 
sulfite. However, absence of elevated urine sulfite 
excretion may also occur in patients with MOCD 
due to rapid degradation resulting from delay 
in processing of the sample and therefore, it is 
essential to test sulfite levels in a freshly voided 
urine sample (5).
Brain MRI findings in MOCD closely resemble 
the pattern observed in neonates with hypoxic-
ischaemic encephalopathy. MRI findings 
described in patients with isolated sulfite oxidase 
or MOCD are cerebral edema, cerebral atrophy, 
cerebellar atrophy,basal ganglia calcification, 
cystic encephalomalacia, ventriculomegaly, signal 
changes in internal capsule, external capsule 
and subcortical white matter tracts,  delayed 
myelination, cystic changes in basal ganglia, 
hypoplasia of corpus callosum, brainstem and 
basal ganglia (6,7). MRI findings observed in 
our patient are cystic encephalomalacia, signal 
changes in the white matter and basal ganglia, 
thinning of corpus callosum. Diffusion restriction 
noted along the corticospinal tract in our case is a 
novel imaging finding. Widespread or non-uniform 
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pattern of diffusion restriction in the cortical and 
subcortical regions have been reported in infants 
with MOCD deficiency (8,9). Elevated lactate 
peak was observed in our patient as described in 
a previous report (2). It could possibly be due to 
energy failure resulting from neurotoxic effect of 
sulfite on the mitochondria.
Three types of MOCD have been described based 
on the genetic defect that includes type 1 due to 
MOCS1 mutation, type 2 due to MOCS2 mutation 
and type 3 due to GEPHYRIN mutation. A novel 
homozygous mutation was identified in exon 4 
of MoCS2 gene in our patient and has not been 
reported previously in the literature.
Patients with MOCD type A have deficiency of 
cPMP and early initiation of treatment with 80-
320 mcg/kg/d of cPMP was found to be beneficial 
(2, 10). Other measures tried in the management 
of children with isolated sulfite oxidase or 
molybdenum cofactor deficiency includes 
administration of anticonvulsants, restriction 
of sulfur-containing amino acids in diet, use of 
dextromethorphan, use of d-penicillamine to bind 
sulfites and addressing the feeding and respiratory 
difficulties (11-14).
In conclusion, MOCD must be considered in all 
neonates and infants with microcephaly, refractory 
seizures, and developmental delay with or without 
ectopia lentis. Infants with MOCD have distinctive 
imaging findings mimicking hypoxic-ischaemic 
encephalopathy. Screening of all neonates for 
urinary sulfite metabolites helps in early diagnosis. 
More research is needed to explore further 
treatment options in this otherwise lethal disorder.
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